Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06699420
PHASE4

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

Sponsor: Qilu Hospital of Shandong University

View on ClinicalTrials.gov

Summary

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

Official title: The Efficacy and Safety of Qishenyiqi Dripping Pill in Patients With Coronary Microvascular Disease

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

162

Start Date

2023-11-08

Completion Date

2026-06-30

Last Updated

2024-11-21

Healthy Volunteers

No

Interventions

DRUG

Qishenyiqi dripping pills 1 bag, three times a day

Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months

DRUG

Placebo 1 bag, three times a day

Placebo, 1 bag once, three times a day, 12 months

Locations (3)

Qianfoshan Hospital, Shandong University

Jinan, Shandong, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Jinan Central Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, China